title: [Serious QT interval prolongation associated with velafaxine administration].
authors.affiliation: Servicio de Farmacia. Hospital Universitario Severo Ochoa. Leganés. Madrid. España.. noerual@hotmail.com.
authors.forename: Noelia
authors.initials: N
authors.lastname: Rubio Álvaro
authors.affiliation: Servicio de Farmacia. Hospital Universitario Severo Ochoa. Leganés. Madrid. España..
authors.forename: Pilar
authors.initials: P
authors.lastname: Tejedor Prado
authors.affiliation: Servicio de Farmacia. Hospital Universitario Severo Ochoa. Leganés. Madrid. España..
authors.forename: Francisco José
authors.initials: FJ
authors.lastname: Hidalgo Correas
authors.affiliation: Servicio de Farmacia. Hospital Universitario Severo Ochoa. Leganés. Madrid. España..
authors.forename: Benito
authors.initials: B
authors.lastname: García Diaz
mesh_terms: D054058:Acute Coronary Syndrome / Q000175:diagnosis / Q000188:drug therapy; D000328:Adult; D000928:Antidepressive Agents / Q000009:adverse effects*; D002317:Cardiovascular Agents / Q000627:therapeutic use; D003951:Diagnostic Errors; D057915:Drug Substitution; D004562:Electrocardiography; D006801:Humans; D008133:Long QT Syndrome / Q000139:chemically induced* / Q000175:diagnosis; D008297:Male; D020280:Sertraline / Q000627:therapeutic use; D026941:Sodium Channel Blockers / Q000009:adverse effects; D013616:Tachycardia, Sinus / Q000139:chemically induced / Q000175:diagnosis / Q000188:drug therapy; D000069470:Venlafaxine Hydrochloride / Q000009:adverse effects*
chemical_list: D000928:Antidepressive Agents; D002317:Cardiovascular Agents; D026941:Sodium Channel Blockers; D000069470:Venlafaxine Hydrochloride; D020280:Sertraline